Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 9/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 7/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 7/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11750711 | 0.82 | ENPP2 (0.78) | ENPP2SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL5582571 | 0.80 | TGM2 (0.54) | ENPP2 | |
| SCHEMBL14473182 | 0.77 | ABL1 (0.46) | SMN1; SMN2ABL1RIN1 | |
| SCHEMBL2476561 | 0.77 | ENPP2 (0.70) | ENPP2SMN1; SMN2NPC1RAB9AHTT | |
| Hydrochloric Acid SCHEMBL5681091 | 0.76 | ENPP2 (0.66) | ENPP2SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL5347279 | 0.76 | ENPP2 (0.68) | ENPP2SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL12771582 | 0.76 | ENPP2 (0.65) | ENPP2SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL13388216 | 0.75 | ENPP2 (0.67) | ENPP2SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL15379737 | 0.75 | ENPP2 (0.64) | ENPP2SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL5582856 | 0.74 | SIGMAR1 (0.52) | SMN1; SMN2ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | claimed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | ENPP2 3258/4885SMN1; SMN2 3652/4885NPC1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.